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1. Introduction 
Serum high density lipoprotein (HDL) plays a 
major role in the transport and metabolism of 
cholesterol which is mediated through its interaction 
with the enzyme lecithin: cholesterol acyltransferase 
(LCAT) [l] . Evidence has also been presented that 
HDL facilitates the uptake of cholesterol from peri- 
pheral tissues and the clearance of cholesterol from 
arterial wall [2] . Furthermore, decreased HDL and 
HDL cholesterol levels were shown to be correlated 
to the incidence of coronary heart disease [3,4] . 
HDL contains two major apoprotein components 
which have been designated apoprotein A-I (apo A-I) 
and apoprotein A-II (apo A-II) [5-71. These two 
protein moieties account for 90% of the total protein 
content of HDL [8] , and are believed to be of central 
importance not only for the structural but also for 
the functional integrity of HDL. Apo A-I has been 
shown to activate LCAT in vitro [9] and to remove 
cholesterol from the aortic smooth muscle cells [lo] . 
Rapid and precise measurement of apo A-I and 
apo A-II would be valuable in elucidating their struc- 
tural and physiological functions. To this end we have 
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raised antisera against human apo A-I and apo A-II 
and developed a specific solid phase radioimmuno- 
assay for their quantitation. 
2. Materials and methods 
2.1.Sera 
Sera were taken from normolipidemic males and 
females after a 12 h fast. The sera were delipidated 
by ether-ethanol [ 111 or by 1 ,1,3,3 ,-tetramethyl 
urea (TMU) [ 121. 
2.2. Preparation of lipoproteins and apoproteins 
HDL was isolated from individual donors by 
sequential ultracentrifugation [ 133 and repeatedly 
delipidated with 4 vol. acetone (twice), heptane 
(twice), ether-ethanol (1: 1) (twice) and ether 
(once). The residue was finally dried under Na. The 
delipidated HDL was chromatographed on Sephadex 
G-150 in 6 M urea, 0.03 M Tris-HCl, pH 8.2 [14], 
and the fractions containing both apo A-I and apo 
A-II, respectively, were rechromatographed on DEAE 
cellulose in 6 M urea [7 ,15 ,161. Purity of isolated 
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apo A-I and apo A-II was assessed by polyacrylamide 
gel electrophoresis in urea. 
2.3. Preparation of antisera against apo A-I and 
apo A-II 
Adult sheep were immunized with 0.5 mg apo A-I 
and apo A-II, respectively, in complete Freund’s 
adjuvant. They were boosted with intervals of 2 weeks 
with the same antigen dose. Bleedings were taken 
after 6 weeks with intervals of 2 weeks. Anti-apo A-I 
antibodies were isolated with an immunoadsorbent 
consisting of apo A-I which was coupled to cyanogen 
bromide-activated Sepharose 4B using the procedure 
in [ 171 . Antisera against apo A-II were passed over 
the apo A-I Sepharose column in order to adsorb 
anti-apo A-I antibodies. Both antibody preparations 
were monospecific as tested by immunoelectro- 
phoresis and by double diffusion in agar. 
2.4. Radioimmunoassay (RIA) 
For coupling to bromoacetylcellulose (BAC) the 
y-globulin fraction of the anti-apo A-II antiserum was 
precipitated by ammoniumsulphate at 35% saturation. 
Isolated anti-apo A-I antibodies or the -y-globulin 
fraction of the anti-apo A-II antiserum were coupled 
to BAC as described in [ 181. Apo A-I and apo A-II 
were trace-labeled with ‘25I by the chloramine-T 
method [ 191. 
The binding inhibition assay was set up as follows: 
To 140 ~1 RIA buffer (375 ml 0.2 M phosphate, 
pH 7.5,lOO ml EDTA 0.1 M, 10 ml NaN3 2%, 
10 ml BSA 2270,500 ml NaClO.9%, 5 ml Tween 20) 
50 ~1 BAC-conjugate, 10 ~1 dilutions of unlabeled 
antigens and 50 ~1 ‘251-labeled antigen was added. 
The mixture was incubated overnight at 4°C. After 
3 washes with RIA buffer the test tubes containing 
the sedimented BAC conjugate were counted in a 
gamma counter (Nuclear, Chicago). All tests were 
done in duplicate. 
2.5. Other procedures 
Protein concentrations were determined by the 
method in [20]. 
3. Results 
Figure 1 represents the standard curve for the dis- 
placement of ‘251-labeled apo A-I from BAC-anti- 
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Fig.1. Displacement of 12’1 apo A-I from BAC coupled anti-apo A-I by apo A-I (o), HDL (X), LDL (A), VLDL (m) and apo A-II (0). 
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Fig.2. Displacement of “‘I apo A-II from BAC coupled anti-apo A-II by apo A-II (o), HDL (X), LDL (A), VLDL (m) and ape A-I (0). 
apo A-I by unlabeled apo A-I and the displacement 
of 1251-labeled apo A-I by various unlabeled inhibitors 
such as very low density Iipoprotein (VLDL), low 
density lipoprotein (LDL), delipidated and native 
HDL, and apo A-II. Only apo A-I and HDL were 
effective inhibitors indicating that the assay was 
specific for apo A-I. The assay was linear from 
lo-100 ng apo A-I. 
The respective data for apo A-II are displayed in 
fig.2. The monospecificity of the assay for apo A-II 
is indicated by the fact that only apo A-II and HDL 
could effectively displace ‘251-labeled apo A-II from 
BAC-anti-apo A-II. This assay was linear from 
lo-100 ng for apo A-II. 
Denaturation of HDL with TMU did not signifi- 
cantly affect its inhibitory capacity in both assays, 
whereas delipidation with ether-ethanol gave values 
which were about 15% lower than values obtained 
with native HDL or with native sera. 
The data obtained for a collective of 20 normal 
males and 20 normal females from 20-60 years old 
is given in table 1. From day to day analysis (n = 10) 
gave variation coefficients of 7% for the assay of 
apo A-I and 9% for apo A-II. 
Table 1 
Concentration of apo A-I and apo A-II in normal sera 
Apo A-I Apo A-II 
Mean + SD 
(mgldl) 
Range 
(mg/dl) 
Mean f SD 
(mgldl) 
Range 
(mg/dl) 
Males 109 + 13 92 - 129 32~ 4 25 -- 44 
(n = 20) 
Females 124 f 24 98 - 155 37 + 7 2.5 -51 
(n = 20) 
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4. Discussion 
We describe here two sensitive and rapid solid 
phase radioimmunoassays for the two major apo- 
proteins of HDL apo A-I and apo A-II. The assays are 
sensitive in the range IO-100 ng and they are 
specific for apo A-I and apo A-II, respectively. From 
day to day analysis gave variation coefficients of 7% 
for apo A-I and 9% for apo A-II indicating appropriate 
precision for both assays. The analysis time was in 
the order of 15 h which is considerably faster than 
previously reported techniques for the measurement 
of apoproteins of HDL. 
Quantitation of apo A-I using a double antibody 
radioimmunoassay [21-241 or the immunodiffusion 
technique [25] has already been described. These 
authors determined comparable values for apo A-I 
but noted different behaviour upon delipidation. 
While delipidation was not necessary to measure total 
apo A-I in plasma [24], only 5% of the radiolabeled 
apo A-I displaced by delipidated plasma was displaced 
when delipidation with organic solvents was omitted 
[2 1 ] . Without denaturation only 60-80% assayable 
apo A-I was measured [22]. Heating to 52°C was 
used for denaturation [22] Only about 30% apo A-I 
was assayable in native sera as compared to sera 
delipidated with an ether-ethanol mixture [23]. In 
our assay for apo A-I denaturation with TMU did not 
significantly alter the values and seems to be un- 
necessary. Delipidation of sera or HDL with an 
ether-ethanol mixture, however, decreased the 
inhibitory capacity to about 85% values obtained 
with native sera or HDL. The decrease in inhibitory 
capacity is probably due to irreversible denaturation 
of the protein with delipidation by organic solvents. 
The different data observed by the various groups of 
investigators might be due to differences in antigenic 
specificity and affinity of the antibodies used. Our 
antisera were raised in sheep instead of rabbits used 
by the other authors. They were obtained after 
repeated biweekly boosting the animals over a period 
of several months. They probably represent a high 
affinity population of antibodies. 
Quantitation of apo A-II so far has only been per- 
formed in [23]. A radioimmunoassay for apo A-II to 
study antigenic reactive regions of apo A-II has been 
developed [26] . However, serum apo A-II levels were 
determined [26] . The apo A-II concentration in 
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native HDL was 1.4-times greater than that of apo 
HDL [26] . Similar values of apo A-II in native and in 
sera delipidated with ether-ethanol were reported 
[23] , which is in marked contrast to the findings 
with apo A-I [23]. In our assay delipidation with 
organic solvents decreased the inhibitory capacity of 
sera and HDL in the assay for apo A-II to about the 
same extent as in the assay for apo A-I. Apart from 
the differences noted with delipidation our values for 
apo A-I and apo A-II are in reasonable agreement 
with the other data known so far. 
It now seems possible to quantitate both major 
apoproteins of HDL in a rapid and easy way and to 
assess their physiological role. Preliminary results 
from this laboratory indicate that patients with 
coronary heart disease have decreased levels of apo 
A-I while the apo A-II levels appear to be slightly 
increased. These data strengthen the physiological 
importance of the two major apoproteins of HDL. 
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